Drug Database
FO

follitropin alfa

✓ Approved

Cinnagen Co · FSHR · 重组蛋白

什么是 follitropin alfa?

follitropin alfa 是一种重组蛋白,由Cinnagen Co研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Subcutaneous Injection。

药物档案

公司Cinnagen Co
药物类别重组蛋白
分子靶点FSHR
给药途径Injectable (Others), Subcutaneous Injection
状态Approved

作用机制

分子靶点

follitropin alfa 作用于 1 个分子靶点:

FSHRfollicle stimulating hormone receptor (FSHRO, ODG1)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

follitropin alfa 针对 2 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Reproductive system and breast disordersInfertility male✓ Approved
Reproductive system and breast disordersInfertility female✓ Approved

相关研究文献

PubMedDrugs2026-11-17

Insulin Efsitora Alfa: First Approval.

Blair Hannah A HA

Insulin efsitora alfa (Onswik™) is a once-weekly ultra-long-acting recombinant basal insulin being developed by Eli Lilly and Company for the treatment of diabetes mellitus. Administered once weekly as a subcutaneous injection, insulin efsitora alfa is designed to provide a simplified treatment regimen relative to standard daily basal insulins. On 20 August 2026, insulin efsitora alfa received its first approval in the EU for the treatment of type 2 diabetes mellitus (T2DM) in adults. On 24 September 2026, insulin efsitora alfa was approved in the USA as an adjunct to diet and exercise to improve glycemic control in adults with T2DM. Insulin efsitora alfa is approved in the EU, Iceland, Norway, Liechtenstein and the USA and is under regulatory review in the UK and Japan for T2DM. This article summarizes the milestones in the development of insulin efsitora alfa leading to this first approval for T2DM.

PMID 43040187
阅读全文 →
PubMedFrontiers in immunology2026-11-17

Immune-epithelial coordination of barrier repair in inflammatory bowel disease: from cell survival to functional healing.

Wu Ben B, He Bin-Sheng BS

Epithelial repair in inflammatory bowel disease involves preservation of viable cells, coverage of wounds, renewal of epithelial populations and recovery of selective transport and secretion. These processes overlap, yet improvement in one does not establish completion of the others. This narrative review examines how immune signals influence these transitions and how experimental repair findings relate to patient outcomes. We first describe the junctional and mucus barrier and the distinction between physiological, endoscopic and histological measurements. We then examine epithelial death control, regenerative pathways and immune-derived signals using studies selected for compartment-specific perturbation, functional measurements or informative discrepancies between experimental and clinical findings. Interleukin-22 illustrates the importance of context: it promotes regeneration in several experimental systems, disrupts barrier function in a human colon chip, and has not yielded demonstrated efficacy as efmarodocokin alfa in a phase II ulcerative colitis trial. In one small infliximab study, paired measurements from nine patients showed an increase in epithelial resistance after treatment. Larger controlled studies are needed to establish how consistently functional recovery accompanies immune control. We organize the evidence around target engagement, epithelial response, barrier function and patient benefit, with example assays and common interpretive pitfalls for each. The resulting synthesis identifies the measurements needed to distinguish protection from repair and to test whether an epithelial effect adds value to effective immune therapy. Clinical studies must ultimately establish that a specified functional improvement is durable and beneficial to patients.

PMID 43041937
阅读全文 →
PubMedMolecular and cellular endocrinology2026-11-16

Preparations of recombinant follicle-stimulating hormone (FSH) alfa and delta induce different intracellular signals in vitro.

Lazzaretti Clara C, Mercanile Giada G, Perri Carmela C, Mascolo Elisa E et al.

Recombinant follicle-stimulating hormone (FSH)-based drugs Rekovelle® and Gonal-F® are produced in different host cell lines, i.e. the genetically modified human fetal retinal cell line (PER.C6®) and Chinese hamster ovary (CHO), respectively. Source cells lead to hormone preparations with distinct glycosylation profiles, possibly impacting the pattern of hormone-mediated intracellular signaling cascades. In this study, we compared the preparation-specific intracellular signalling pattern and receptor internalization in vitro. In transfected HEK293 cells expressing the FSH receptor (FSHR), we found that Rekovelle® is more potent than Gonal-F® in activating dose-dependent intracellular cAMP and CRE promoter activity, as an issue detectable in the nM concentrations range. Interestingly, Rekovelle® had a biphasic behaviour on the cAMP-pathway, since the 1 μM drug concentration (33.3 μg/ml) leads to inhibition of cAMP and CRE response, which did not occur with the equimolar Gonal-F® concentration. This event was accompanied by recruitment of β-arrestin 2 and FSHR routing to the late endosomes. To evaluate whether cAMP and CRE inhibition by 1 μM Rekovelle® depends on FSHR internalization, FSH dose-response experiments were performed in β-arrestin 2 knockout HEK293 cell line, where 1 μM Rekovelle® resulted in an intracellular cAMP increase. In conclusion, we found the mechanism underlying different modes of action between follitropin alfa and delta, as an issue likely linked to different glycan profiles, supporting the rationale for a tailored clinical use of these drugs.

PMID 43039287
阅读全文 →
PubMedTherapeutic advances in rare disease2026-11-16

Patient perspectives of participation in clinical studies in late-onset Pompe disease: Structured exit interviews from cipaglucosidase alfa plus miglustat studies.

Gault Jamie J, Amon Farah F, Clarke Sophie S, Holdbrook Fred F et al.

Cipaglucosidase alfa plus miglustat (cipa+mig) is an approved treatment in many countries for adults living with late-onset Pompe disease. To capture patient insights into clinical studies. We conducted an exit interview study based on the 2022 US Food and Drug Administration (FDA) guidance recommending structured interviews. We conducted structured exit interviews with participants (≥18 years) in the UK or USA who completed the final visit or had data available at the final data cut-off date for three long-term clinical trials (ATB200-02 [NCT02675465], ATB200-04 [NCT03911505], and ATB200-07 [NCT04138277]) and from the cipa+mig UK Early Access to Medicines Scheme (EAMS). Participants were asked to rate their experience with the study conduct, using a two-component therapy, and disease-specific and general quality-of-life (QoL) outcomes. Of 91 eligible participants, 23 (13 male) completed an exit interview (clinical trials n=19; EAMS n=4). For most participants (83%), looking for another treatment option and/or wanting to contribute to drug development was the motivation for joining a study. Almost all participants stated they were provided with appropriate information before joining the study (96%), and the time commitment was acceptable (91%). Most participants (74%) did not find the process of taking the two-component therapy challenging, while the remaining 26% had neutral experiences. Around half (52%) rated the fasting process before taking mig as very convenient or convenient; 39% were neutral, and 9% rated the fasting process as mildly inconvenient. Finally, 57% of participants felt that cipa+mig provided benefits and improved their QoL. Overall, alongside perceived improvements in disease-specific and QoL outcomes, participants found taking the two-component therapy neither challenging nor inconvenient. These exit interviews provide valuable insights into patient perspectives of cipa+mig and study processes not captured using standard patient-reported outcome measures and should be considered in future studies in line with FDA guidance.

PMID 43036470
阅读全文 →
PubMedClinical pharmacokinetics2026-11-15

Exploration of Extravascular Tissue and Synovial Fluid Distribution of Extended Half-Life Factor IX Concentrates by Physiologically Based Pharmacokinetic Modelling.

Koopman Sjoerd F SF, Sjögren Erik E, Lenting Peter J PJ, Cnossen Marjon H MH et al.

Extended half-life factor IX (EHL-FIX) concentrates are a mainstay of prophylactic treatment in haemophilia B due to their prolonged plasma half-life and less frequent administration. Plasma FIX activity levels do not necessarily correlate with haemostatic efficacy, possibly due to its extravascular tissue distribution while still contributing to haemostasis. Importantly, tissue-specific exposure of EHL-FIX concentrates remains insufficiently characterised. We aimed to characterise and compare FIX distribution across plasma, extravascular and synovial tissue using physiologically based pharmacokinetic (PBPK) modelling. PBPK models were developed in PK-Sim®/MoBi® to simulate plasma concentration-time profiles following a 50 IU/kg dose of eftrenonacog alfa (rFIX-Fc), albutrepenonacog alfa (rIX-FP) and nonacog beta pegol (N9-GP). The models incorporated binding affinity (Kd) to collagen type IV (Col4), the neonatal Fc receptor (FcRn) and a vascular endothelial binding partner. A synovium module was implemented to estimate joint-specific exposure. Predicted extravascular distribution profiles differed markedly among EHL-FIX concentrates. rFIX-Fc demonstrated the greatest extravascular distribution, followed by rIX-FP, whereas N9-GP showed minimal distribution. For rFIX-Fc and rIX-FP, highest exposure was predicted in the spleen, lung and kidney. KdFcRn was higher for rFIX-Fc than rIX-FP, while KdCol4 was comparable. No KdCol4 for N9-GP was identified. Synovial fluid concentration predictions indicated highest exposure for rFIX-Fc, modest exposure for rIX-FP and limited exposure for N9-GP. The constructed PBPK models provide a mechanistic framework for predicting distinct plasma and tissue-specific distribution profiles for three EHL-FIX concentrates, offering a quantitative basis for exploration of the relationship between extravascular and synovial exposure and bleeding outcomes in haemophilia B.

PMID 43034964
阅读全文 →
PubMedRespiratory medicine case reports2026-11-15

Fulminant human rhinovirus C pneumonia after allogeneic hematopoietic cell transplantation supported with venovenous extracorporeal membrane oxygenation: a case report.

Huang Qixiang Q, Peng Yanping Y, Zhan Yian Y, Zhou Ting T et al.

Human rhinovirus C (HRV-C) can cause severe lower respiratory tract disease after allogeneic hematopoietic cell transplantation (allo-HCT), but evidence supporting extracorporeal membrane oxygenation (ECMO) in this setting is sparse. A 21-year-old Han Chinese man with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia developed rapidly progressive pneumonia approximately 3 months after paternal haploidentical allo-HCT. Bilateral ground-glass opacities progressed despite empirical antimicrobial therapy. Metagenomic next-generation sequencing of bronchoalveolar lavage fluid detected HRV-C (1136 sequence reads, 440 normalized reads; estimated concentration, 2.4 × 104 copies/mL) without another reported pathogen. Before extracorporeal support, a final arterial blood gas showed PaO2 40 mmHg and PaCO2 80 mmHg, consistent with severe combined hypoxemic and hypercapnic respiratory failure. He also had a blood pressure of 70/35 mmHg despite norepinephrine at 0.2-0.3 μg/kg/min, serum lactate of 3.6 mmol/L, and urine output of approximately 800 mL/24 h. He underwent intubation and venovenous ECMO. Off-label adjunctive therapy comprised intravenous ribavirin 500 mg twice daily for 7 days, subcutaneous interferon alfa-2b 3 million IU once daily for 7 days, and methylprednisolone. He was extubated on November 11, ECMO was discontinued on November 12 after 9 days, and he was discharged without supplemental oxygen. This case illustrates the potential severity of HRV-C after allo-HCT and time-limited venovenous ECMO support in a carefully selected patient with a potentially reversible pulmonary process.

PMID 43032274
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多follitropin alfa